• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)

    Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex)

  2. KaloBios Elects Ronald A. Martell to Board of Directors

    KaloBios Elects Ronald A. Martell to Board of Directors

  3. ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results

    ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2015 Financial Results

  4. Zynga Chief Operating Officer Clive Downie Resigns

    Zynga Chief Operating Officer Clive Downie Resigns

  5. How the Hottest Biotech Sprouted in Iowa

    How the Hottest Biotech Sprouted in Iowa

  6. Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015

    Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015

  7. Social Security Tips For Couples

    Genentech DNA reported strong first-quarter revenue and earnings growth compared with the year-ago period, and we are sticking with our fair value estimate. As the company warned at its investor meeting in March, quarter-over-quarter product sales growth was stagnant, while total revenue growth ...

  8. Tuttle Tactical Management Weekly Market Commentary

    Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...

  9. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.